UBS raised the firm’s price target on United Therapeutics (UTHR) to $600 from $580 and keeps a Buy rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics announces first clinical xenotransplantation in EXPAND study
- United Therapeutics price target raised to $587 from $569 at RBC Capital
- United Therapeutics price target raised to $525 from $500 at H.C. Wainwright
- United Therapeutics price target raised to $447 from $435 at Morgan Stanley
- United Therapeutics: Hold Rating Amid Optimistic Partnership Prospects and Adjusted Revenue Goals